Personal Home Page

http://www.gmu.edu/departments/lifesciences/proteomics/petricoin.htm

Articles in Scholarly Journals [Incomplete List]

1. A New Scientific Journal Linked to a Genetic Database: Towards a Novel Publication Modality
   Human Genomics and Proteomics, vol. 2009, Article ID 597478, 2 pages, 2009
2. Smart Hydrogel Particles: Biomarker Harvesting: One-Step Affinity Purification, Size Exclusion, and Protection against Degradation
   Nano Letters, vol. 8, no. 1, pp. 350–361, 2008
3. Human Proteinpedia enables sharing of human protein data
   Nature Biotechnology, vol. 26, no. 2, Article ID nbt0208-164, 3 pages, 2008
4. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks
   Nature Reviews Drug Discovery, vol. 6, no. 11, Article ID nrd2381, 9 pages, 2007
5. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition
   Oncogene, vol. 27, no. 3, Article ID 1210647, 8 pages, 2007
6. The needle in the haystack: Application of breast fine-needle aspirate samples to quantitative protein microarray technology
   Cancer, vol. 111, no. 3, pp. 173–184, 2007
7. Reply:
   Hepatology, vol. 46, no. 4, pp. 1306–1307, 2007
8. A method for the selective isolation and enrichment of carrier protein-bound low-molecular weight proteins and peptides in the blood
   PROTEOMICS – Clinical Applications, vol. 1, no. 2, pp. 176–184, 2007
9. Physicochemically modified silicon as a substrate for protein microarrays
   Biomaterials, vol. 28, no. 3, pp. 550–558, 2007
10. Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression
    American Journal Of Pathology, vol. 171, no. 5, pp. 1650–1658, 2007
11. Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer
    Annals of Surgical Oncology, vol. 14, no. 9, pp. 2470–2476, 2007
12. A Novel, High-Throughput Workflow for Discovery and Identification of Serum Carrier Protein-Bound Peptide Biomarker Candidates in Ovarian Cancer Samples
    Clinical Chemistry, vol. 53, no. 6, pp. 1067–1074, 2007
13. Putting the "Bio" back into Biomarkers: Orienting Proteomic Discovery toward Biology and away from the Measurement Platform
    Clinical Chemistry, vol. 54, no. 1, pp. 3–5, 2007
14. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine
    Expert Review of Molecular Diagnostics, vol. 7, no. 5, pp. 625–633, 2007
15. Mathematical Modeling of the Cancer Cell’s Control Circuitry: Paving the Way to Individualized Therapeutic Strategies
    Current Signal Transduction Therapy, vol. 2, no. 2, pp. 145–155, 2007
16. Combination of SELDI-TOF-MS and Data Mining Provides Early-stage Response Prediction for Rectal Tumors Undergoing Multimodal Neoadjuvant Therapy
    Annals of Surgery, vol. 245, no. 2, pp. 259–266, 2007
17. Differentiation of tumour-stage mycosis fungoides, psoriasis vulgaris and normal controls in a pilot study using serum proteomic analysis
    British Journal of Dermatology, vol. 157, no. 5, pp. 946–953, 2007
18. Phosphoprotein Pathway Mapping: Akt/Mammalian Target of Rapamycin Activation Is Negatively Associated with Childhood Rhabdomyosarcoma Survival
    Cancer Research, vol. 67, no. 7, pp. 3431–3440, 2007
19. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study
    Molecular Cancer Therapeutics, vol. 6, no. 3, pp. 820–832, 2007
20. Lysophosphatidic Acid Down-Regulates Stress Fibers and Up-Regulates Pro-Matrix Metalloproteinase-2 Activation in Ovarian Cancer Cells
    Molecular Cancer Research, vol. 5, no. 2, pp. 121–131, 2007
21. Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans
    Blood, vol. 110, no. 2, pp. 501–508, 2007
22. Discovering Clinical Biomarkers of Ionizing Radiation Exposure with Serum Proteomic Analysis
    Cancer Research, vol. 66, no. 3, pp. 1844–1850, 2006
23. Breast Cancer Growth Prevention by Statins
    Cancer Research, vol. 66, no. 17, pp. 8707–8714, 2006
24. Secreted Neutral Metalloproteases of Bacillus anthracis as Candidate Pathogenic Factors
    Journal of Biological Chemistry, vol. 281, no. 42, pp. 31408–31418, 2006
25. Dynamic Profiling of the Post-translational Modifications and Interaction Partners of Epidermal Growth Factor Receptor Signaling after Stimulation by Epidermal Growth Factor Using Extended Range Proteomic Analysis (ERPA)
    Molecular & Cellular Proteomics, vol. 5, no. 9, pp. 1610–1627, 2006
26. Role of proteomics in personalized medicine
    Personalized Medicine, vol. 3, no. 3, pp. 223–226, 2006
27. Clinical phosphoproteomic profiling for personalized targeted medicine using reverse phase protein microarray
    Targeted Oncology, vol. 1, no. 3, pp. 151–167, 2006
28. Nanoparticles: potential biomarker harvesters
    Current Opinion in Chemical Biology, vol. 10, no. 1, pp. 56–61, 2006
29. The amplified peptidome: the new treasure chest of candidate biomarkers
    Current Opinion in Chemical Biology, vol. 10, no. 1, pp. 50–55, 2006
30. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer
    The Journal of Pathology, vol. 208, no. 5, pp. 595–606, 2006
31. Technology Insight: pharmacoproteomics for cancer—promises of patient-tailored medicine using protein microarrays
    Nature Clinical Practice Oncology, vol. 3, no. 5, Article ID ncponc0485, 12 pages, 2006
32. Laser-capture microdissection
    Nature Protocols, vol. 1, no. 2, Article ID nprot.2006.85, 17 pages, 2006
33. The blood peptidome: a higher dimension of information content for cancer biomarker discovery
    Nature Reviews Cancer, vol. 6, no. 12, Article ID nrc2011, 6 pages, 2006
34. Journal of Proteome Research, vol. 5, no. 5, pp. 1261–1266, 2006
35. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis
    Experimental Hematology, vol. 34, no. 6, pp. 796–801, 2006
36. Selective binding and enrichment for low-molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles
    PROTEOMICS, vol. 6, no. 11, pp. 3243–3250, 2006
37. Protein pathway analysis in Clinical Proteomics using protein microarrays
    Drug Discovery Today: Technologies, vol. 2, no. 4, pp. 353–359, 2005
38. Bioconjugate Chemistry, vol. 16, no. 3, pp. 559–566, 2005
39. Clinical Proteomics: From Biomarker Discovery and Cell Signaling Profiles to Individualized Personal Therapy
    Bioscience Reports, vol. 25, no. 1-2, pp. 107–125, 2005
40. A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis
    Arthritis & Rheumatism, vol. 52, no. 3, pp. 902–910, 2005
41. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis
    Clinica Chimica Acta, vol. 357, no. 2, pp. 180–183, 2005
42. A mathematical model of combination therapy using the EGFR signaling network
    Biosystems, vol. 80, no. 1, pp. 57–69, 2005
43. Analysis of Albumin-Associated Peptides and Proteins from Ovarian Cancer Patients
    Clinical Chemistry, vol. 51, no. 10, pp. 1933–1945, 2005
44. CSF proteome: a protein repository for potential biomarker identification
    Expert Review of Proteomics, vol. 2, no. 1, pp. 57–70, 2005
45. Cancer proteomics: many technologies, one goal
    Expert Review of Proteomics, vol. 2, no. 5, pp. 693–703, 2005
46. Mapping Molecular Networks Using Proteomics: A Vision for Patient-Tailored Combination Therapy
    Journal of Clinical Oncology, vol. 23, no. 15, pp. 3614–3621, 2005
47. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma
    Endocrine Related Cancer, vol. 12, no. 2, pp. 263–272, 2005
48. Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma
    Molecular & Cellular Proteomics, vol. 4, no. 4, pp. 346–355, 2005
49. Pathology of the Future: Molecular Profiling for Targeted Therapy
    Cancer Investigation, vol. 23, no. 1, pp. 36–46, 2005
50. Analysis of mass spectral serum profiles for biomarker selection
    Bioinformatics, vol. 21, no. 21, pp. 4039–4045, 2005
51. Importance of Communication Between Producers and Consumers of Publicly Available Experimental Data
    CancerSpectrum Knowledge Environment, vol. 97, no. 4, pp. 310–314, 2005
52. Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma
    Clinical Cancer Research, vol. 11, no. 16, pp. 5847–5855, 2005
53. Modeling of Protein Signaling Networks in Clinical Proteomics
    Cold Spring Harbor Symposia on Quantitative Biology, vol. 70, no. 1, pp. 517–524, 2005
54. Supra-additive Growth Inhibition by a Celecoxib Analogue and Carboxyamido-triazole Is Primarily Mediated through Apoptosis
    Cancer Research, vol. 65, no. 9, pp. 3853–3860, 2005
55. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment
    Journal of Clinical Investigation, vol. 115, no. 5, pp. 1163–1176, 2005
56. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold
    Journal of Clinical Investigation, vol. 116, no. 1, pp. 26–30, 2005
57. Clinical Proteomics and Biomarker Discovery
    Annals of the New York Academy of Sciences, vol. 1022, no. 1, pp. 295–305, 2004
58. Serum Proteomics in Cancer Diagnosis and Management *
    Annual Review of Medicine, vol. 55, no. 1, pp. 97–112, 2004
59. Blasting into the Microworld of Tissue Proteomics: A New Window on Cancer: Commentary re S. A. Schwartz et al., Protein Profiling in Brain Tumors Using Mass Spectrometry: Feasibility of a New Technique for the Analysis of Protein Expression. Clin. Cancer Res., 10: 981-987, 2004.
    Clinical Cancer Research, vol. 10, no. 3, pp. 825–827, 2004
60. SERUM PROTEOMIC PROFILING CAN DISCRIMINATE PROSTATE CANCER FROM BENIGN PROSTATES IN MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS BETWEEN 2.5 AND 15.0 NG/ML
    The Journal of Urology, vol. 172, no. 4, pp. 1302–1305, 2004
61. Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection
    Toxicologic Pathology, vol. 32, no. 6, pp. 122–130, 2004
62. Molecular Profiling of Cancer
    Toxicologic Pathology, vol. 32, no. 6, pp. 67–71, 2004
63. Application of Laser Capture Microdissection and Protein MicroArray Technologies in the Molecular Analysis of Airway Injury Following Pollution Particle Exposure
    Journal of Toxicology and Environmental Health Part A, vol. 67, no. 11, pp. 851–861, 2004
64. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray
    Laboratory Investigation, vol. 84, no. 2, Article ID 3700051, 9 pages, 2004
65. Use of proteomic analysis to monitor responses to biological therapies
    Expert Opinion on Biological Therapy, vol. 4, no. 1, pp. 83–93, 2004
66. High-resolution serum proteomic features for ovarian cancer detection
    Endocrine Related Cancer, vol. 11, no. 2, pp. 163–178, 2004
67. High-resolution serum proteomic patterns for ovarian cancer detection
    Endocrine Related Cancer, vol. 11, no. 4, pp. 583–584, 2004
68. Clarification in the Point/Counterpoint Discussion Related to Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometric Identification of Patients with Adenocarcinomas of the Prostate * Proteomic Pattern Complexity Reveals a Rich and Uncharted Continent of Biomarkers
    Clinical Chemistry, vol. 50, no. 8, pp. 1475–1477, 2004
69. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer
    Current Opinion in Biotechnology, vol. 15, no. 1, pp. 24–30, 2004
70. Network-targeted combination therapy: a new concept in cancer treatment
    Drug Discovery Today: Therapeutic Strategies, vol. 1, no. 4, pp. 425–433, 2004
71. Lessons from Kitty Hawk: From feasibility to routine clinical use for the field of proteomic pattern diagnostics
    PROTEOMICS, vol. 4, no. 8, pp. 2357–2360, 2004
72. Mitochondrial proteome: Cancer-altered metabolism associated with cytochromec oxidase subunit level variation
    PROTEOMICS, vol. 4, no. 9, pp. 2789–2795, 2004
73. An investigation into the human serum“interactome”
    ELECTROPHORESIS, vol. 25, no. 9, pp. 1289–1298, 2004
74. Proteomic analysis of lymph
    PROTEOMICS, vol. 4, no. 3, pp. 753–765, 2004
75. Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP)
    PROTEOMICS, vol. 4, no. 3, pp. 812–818, 2004
76. Molecular Technologies for Personalized Cancer Management
    JAMA: The Journal of the American Medical Association, vol. 291, no. 13, pp. 1644–1645, 2004
77. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
    Cancer Cell, vol. 5, no. 1, pp. 103–103, 2004
78. Journal of Proteome Research, vol. 3, no. 2, pp. 209–217, 2004
79. Opportunities for Nanotechnology-Based Innovation in Tissue Proteomics
    Biomedical Microdevices, vol. 6, no. 3, pp. 231–239, 2004
80. Genomic and proteomic technologies for individualisation and improvement of cancer treatment
    European Journal of Cancer, vol. 40, no. 17, pp. 2623–2632, 2004
81. Biomarkers of ovarian tumours
    European Journal of Cancer, vol. 40, no. 17, pp. 2604–2612, 2004
82. Importance of disclosure of patent applications
    The Lancet, vol. 364, no. 9434, pp. 577–578, 2004
83. Department of Error
    The Lancet, vol. 364, no. 9434, p. 582, 2004
84. Trapping radioactive carbon dioxide during cellular metabolic assays under standard culture conditions: description of a unique gas-capturing device
    Journal of Biochemical and Biophysical Methods, vol. 58, no. 2, pp. 119–124, 2004
85. Protein microarray detection strategies: focus on direct detection technologies
    Journal of Immunological Methods, vol. 290, no. 1-2, pp. 121–133, 2004
86. Proteomic approaches in cancer risk and response assessment
    Trends in Molecular Medicine, vol. 10, no. 2, pp. 59–64, 2004
87. Use of proteomic patterns to screen for gastrointestinal malignancies
    Surgery, vol. 135, no. 3, pp. 243–247, 2004
88. Clinical proteomics: Applications for prostate cancer biomarker discovery and detection
    Urologic Oncology: Seminars and Original Investigations, vol. 22, no. 4, pp. 322–328, 2004
89. Protein microarrays: Meeting analytical challenges for clinical applications
    Cancer Cell, vol. 3, no. 4, pp. 317–325, 2003
90. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
    Cancer Cell, vol. 4, no. 6, pp. 437–450, 2003
91. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays
    PROTEOMICS, vol. 3, no. 11, pp. 2085–2090, 2003
92. Protein microarrays: Molecular profiling technologies for clinical specimens
    PROTEOMICS, vol. 3, no. 11, pp. 2091–2100, 2003
93. Signal pathway profiling of prostate cancer using reverse phase protein arrays
    PROTEOMICS, vol. 3, no. 11, pp. 2142–2146, 2003
94. Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications
    PROTEOMICS, vol. 3, no. 4, pp. 413–421, 2003
95. Mitochondrial proteome: Altered cytochromec oxidase subunit levels in prostate cancer
    PROTEOMICS, vol. 3, no. 9, pp. 1801–1810, 2003
96. Molecular diagnostics: an FDA perspective
    Expert Review of Molecular Diagnostics, vol. 3, no. 2, pp. 129–140, 2003
97. Cancer diagnosis using proteomic patterns
    Expert Review of Molecular Diagnostics, vol. 3, no. 4, pp. 411–420, 2003
98. Mass Spectrometry-based Diagnostics: The Upcoming Revolution in Disease Detection
    Clinical Chemistry, vol. 49, no. 4, pp. 533–534, 2003
99. Drosophila screening model for metastasis: Semaphorin 5c is required for l(2)gl cancer phenotype
    Proceedings of the National Academy of Sciences, vol. 100, no. 20, pp. 11463–11468, 2003
100. Utility of reverse phase protein arrays: Applications to signalling pathways and human body arrays
     Briefings in Functional Genomics and Proteomics, vol. 1, no. 3, pp. 305–315, 2002
101. Proteomic Evaluation of Archival Cytologic Material Using SELDI Affinity Mass Spectrometry Potential for Diagnostic Applications
     American Journal of Clinical Pathology, vol. 118, no. 6, pp. 870–876, 2002
102. Proteomic analysis of human prostate cancer
     Molecular Carcinogenesis, vol. 33, no. 1, pp. 9–15, 2002
103. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer
     PROTEOMICS, vol. 2, no. 1, pp. 76–84, 2002
104. Genomics and proteomics: application of novel technology to early detection and prevention of cancer
     Cancer Detection and Prevention, vol. 26, no. 4, pp. 249–255, 2002
105. Use of proteomic patterns in serum to identify ovarian cancer
     The Lancet, vol. 359, no. 9306, pp. 572–577, 2002
106. Journal of Mammary Gland Biology and Neoplasia, vol. 7, no. 4, pp. 433–440, 2002
107. Clinical proteomics: translating benchside promise into bedside reality
     Nature Reviews Drug Discovery, vol. 1, no. 9, Article ID nrd891, 12 pages, 2002
108. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front
     Oncogene, vol. 20, no. 16, Article ID 1204265, 8 pages, 2001
109. Molecular profiling of cancer and drug-induced toxicity using new proteomic technologies
     Current Therapeutic Research, vol. 62, no. 11, pp. 803–819, 2001
110. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics
     Urology, vol. 57, no. 4, pp. 160–163, 2001
111. Clinical Proteomics: Personalized Molecular Medicine
     JAMA: The Journal of the American Medical Association, vol. 286, no. 18, pp. 2211–2214, 2001
112. Fingerprinting of signal transduction pathways using a combination of anti-phosphotyrosine immunoprecipitations and two-dimensional polyacrylamide gel electrophoresis
     ELECTROPHORESIS, vol. 22, no. 10, pp. 2120–2124, 2001
113. New approaches to proteomic analysis of breast cancer
     PROTEOMICS, vol. 1, no. 10, pp. 1205–1215, 2001
114. Proteomic profiling of the cancer microenvironment by antibody arrays
     PROTEOMICS, vol. 1, no. 10, pp. 1271–1278, 2001
115. 2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers
     Molecular & Cellular Proteomics, vol. 1, no. 2, pp. 117–123, 2001
116. Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip
     Drug Development Research, vol. 49, no. 1, pp. 34–42, 2000
117. An approach to proteomic analysis of human tumors
     Molecular Carcinogenesis, vol. 27, no. 3, pp. 158–165, 2000
118. Proteomic analysis of laser capture microdissected human prostate cancer andin vitro prostate cell lines
     Electrophoresis, vol. 21, no. 11, pp. 2235–2242, 2000
119. Laser capture microdissection: Beyond functional genomics to proteomics
     Molecular Diagnosis, vol. 5, no. 4, pp. 301–307, 2000
120. Breast Cancer Research, vol. 2, no. 1, p. 13, 1999
121. Activation of Raf-1 by Interferon gamma and Oncostatin M Requires Expression of the Stat1 Transcription Factor
     Journal of Biological Chemistry, vol. 273, no. 30, pp. 18701–18704, 1998
122. Phosphorylation Events Modulate the Ability of Interferon Consensus Sequence Binding Protein to Interact with Interferon Regulatory Factors and to Bind DNA
     Journal of Biological Chemistry, vol. 272, no. 15, pp. 9785–9792, 1997
123. Nature, vol. 390, no. 6660, pp. 629–632, 1997
124. Interleukin 12 Induces Tyrosine Phosphorylation and Activation of STAT4 in Human Lymphocytes
     Proceedings of the National Academy of Sciences, vol. 92, no. 16, pp. 7307–7311, 1995
125. Prolactin Activates the Interferon-Regulated p91 Transcription Factor and the Jak2 Kinase by Tyrosine Phosphorylation
     Proceedings of the National Academy of Sciences, vol. 91, no. 15, pp. 7174–7178, 1994
126. Interferon-alpha-induced gene expression: Evidence for a selective effect of ouabain on activation of the ISGF3 transcription complex
     Virology, vol. 190, no. 1, pp. 210–220, 1992